Juan Ramón Padilla-Mendoza

Dr. Juan Ramón Padilla-Mendoza

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CAClaudia Vanessa Arellano-Gutiérrez
Claudia Vanessa Arellano-Gutiérrez
LQLaura Itzel Quintas-Granados
Laura Itzel Quintas-Granados
Hernán CortésHernán Cortés
Hernán Cortés
MCManuel González del Carmen
Manuel González del Carmen
Gerardo Leyva GómezGerardo Leyva Gómez
Gerardo Leyva Gómez
OROctavio Daniel Reyes-Hernández
Octavio Daniel Reyes-Hernández
Cervical cancer (CC) is one of the most common cancers in women, and is linked to human papillomavirus (HPV) infection. The virus oncoprotein E6 binds to p53, resulting in its degradation and allowing uncontrolled cell proliferation. Meanwhile, the HPV E7 protein maintains host cell differentiation by targeting retinoblastoma tumor suppressor. The host cell can ubiquitinate E6 and E7 through UBE2L3, whose expression depends on the interaction between the aryl hydrocarbon receptor (AhR) with Xenobiotic Responsive Elements (XREs) located in the UBE2L3 gene promoter. In this study, we used cell culture to determine the effect of indole-3-carbinol (I3C) over cellular viability, apoptosis, cell proliferation, and mRNA levels of UBE2L3 and CYP1A1. In addition, patients’ samples were used to determine the mRNA levels of UBE2L3 and CYP1A1 genes. We found that I3C promotes the activation of AhR and decreases cell proliferation, possibly through UBE2L3 mRNA induction, which would result in the ubiquitination of HPV E7. Since there is a strong requirement for selective and cost-effective cancer treatments, natural AhR ligands such as I3C could represent a novel strategy for cancer treatment.

29 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
MVMireya Velazquez-Paniagua
Mireya Velazquez-Paniagua
LCLucero Cuazozon-Ferrer
Lucero Cuazozon-Ferrer
Maria-del-Carmen Silva-LuceroMaria-del-Carmen Silva-Lucero
Maria-del-Carmen Silva-Lucero
AGAndres-Ivan Gutierrez-Malacara
Andres-Ivan Gutierrez-Malacara
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body. It discusses the following aspects of the disease. Genetics: VHL disease is caused by mutations in the VHL tumor suppressor gene located on chromosome 3. These mutations can be inherited or occur spontaneously. This article details the different types of mutations and their associated clinical features. Pathophysiology: The underlying cause of VHL disease is the loss of function of the VHL protein (pVHL). This protein normally regulates hypoxia-inducible factors (HIFs), which are involved in cell growth and survival. When pVHL is dysfunctional, HIF levels become elevated, leading to uncontrolled cell growth and tumor formation. Clinical Manifestations: VHL disease can affect various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands. Symptoms depend on the location and size of the tumors. Diagnosis: Diagnosis of VHL disease involves a combination of clinical criteria, imaging studies, and genetic testing. Treatment: Treatment options for VHL disease depend on the type and location of the tumors. Surgery is the mainstay of treatment, but other options like radiation therapy may also be used. Challenges: This article highlights the challenges in VHL disease management, including the lack of effective therapies for some tumor types and the need for better methods to monitor disease progression. In conclusion, we emphasize the importance of ongoing research to develop new and improved treatments for VHL disease.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JPJuan Ramón Padilla-Mendoza
Juan Ramón Padilla-Mendoza
Arturo Contis-Montes de ocaArturo Contis-Montes de oca
Arturo Contis-Montes de oca
MRMario Alberto Rodriguez
Mario Alberto Rodriguez
MLMavil López-Casamichana
Mavil López-Casamichana
JBJeni Bolaños
Jeni Bolaños
Israel ReyesIsrael Reyes
Israel Reyes
Protein phosphorylation is a posttranslational modification that is essential for normal cellular processes; however, abnormal phosphorylation is one of the prime causes for alteration of many structural, functional, and regulatory proteins in disease conditions. In cancer, changes in the states of protein phosphorylation in tyrosine residues have been more studied than phosphorylation in threonine or serine residues, which also undergo alterations with greater predominance. In general, serine phosphorylation leads to the formation of multimolecular signaling complexes that regulate diverse biological processes, but in pathological conditions such as tumorigenesis, anomalous phosphorylation may result in the deregulation of some signaling pathways. Cervical cancer (CC), the main neoplasm associated with human papillomavirus (HPV) infection, is the fourth most frequent cancer worldwide. Persistent infection of the cervix with high‐risk human papillomaviruses produces precancerous lesions starting with low‐grade squamous intraepithelial lesions (LSIL), progressing to high‐grade squamous intraepithelial lesions (HSIL) until CC is generated. Here, we compared the proteomic profile of phosphorylated proteins in serine residues from healthy, LSIL, HSIL, and CC samples. Our data show an increase in the number of phosphorylated proteins in serine residues as the grade of injury rises. These results provide a support for future studies focused on phosphorylated proteins and their possible correlation with the progression of cervical lesions.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JPJuan Ramón Padilla-Mendoza
Juan Ramón Padilla-Mendoza
LGLucía Angélica Gómez-López
Lucía Angélica Gómez-López
MLMavil López-Casamichana
Mavil López-Casamichana
Elisa Azuara-LiceagaElisa Azuara-Liceaga
Elisa Azuara-Liceaga
ENOC MARIANO CORTÉS MALAGÓNENOC MARIANO CORTÉS MALAGÓN
ENOC MARIANO CORTÉS MALAGÓN
Israel ReyesIsrael Reyes
Israel Reyes
According to their oncogenic properties, Human Papillomaviruses (HPVs) are classified into two types: Low‐Risk (LR‐HPVs) and High‐Risk Human Papillomaviruses (HR‐HPVs). The immune system naturally controls the majority of HPV infections; however, when the HR‐HPV infection is persistent, the risk of developing cervical cancer increases. Previous studies indicate that multiple‐infection or coinfection with HR‐HPV occurs frequently and can potentiate the development of cervical lesions. This study aimed to establish the HPV coinfection rate in squamous intraepithelial lesions from Mexican patients. For HPV detection, we performed PCR on 55 cervical lesions diagnosed by colposcopy. We detected the presence of HPV infection in 87.27% (48/55) of the lesions; interestingly, HPV coinfection was observed in 70.83% (34/48) of these samples. We also evaluated HPV infection in adjacent areas without morphological changes from 25 samples. The results showed that 80% (20/25) of these were HPV‐positive and, curiously, all presented HPV‐16 infection. In conclusion, our results revealed a high prevalence of HPV coinfection in cervical lesions in Mexican patients, and these results contribute to future research focused on the role that HPV coinfection plays in the development of cervical cancer.

29 July 2025 in Plants
Verified
Journal Article
Open access
PDF file
YVYebran Villegas-Vázquez
Yebran Villegas-Vázquez
JPJuan Ramón Padilla-Mendoza
Juan Ramón Padilla-Mendoza
MCMayra Susana Carrillo-Pérez
Mayra Susana Carrillo-Pérez
RGRocío Gómez-Cansino
Rocío Gómez-Cansino
LALiliana Altamirano-Garcia
Liliana Altamirano-Garcia
LQLaura Itzel Quintas-Granados
Laura Itzel Quintas-Granados
Moringa oleifera (MO), a nutritionally and pharmacologically potent species, is emerging as a sustainable candidate for applications across bioenergy, agriculture, textiles, pharmaceuticals, and biomedicine. This review explores recent advances in MO-based biotechnologies, highlighting novel extraction methods, green nanotechnology, and clinical trial findings. Although MO’s resilience offers promise for climate-smart agriculture and public health, challenges remain in standardizing cultivation and verifying therapeutic claims. This work underscores MO’s translational potential and the need for integrative, interdisciplinary research. MO is used in advanced materials, like electrospun fibers and biopolymers, showing filtration, antibacterial, anti-inflammatory, and antioxidant properties—important for the biomedical industry and environmental remediation. In textiles, it serves as an eco-friendly alternative for wastewater treatment and yarn sizing. Biotechnological advancements, such as genome sequencing and in vitro culture, enhance traits and metabolite production. MO supports green biotechnology through sustainable agriculture, nanomaterials, and biocomposites. MO shows potential for disease management, immune support, metabolic health, and dental care, but requires further clinical trials for validation. Its resilience is suitable for land restoration and food security in arid areas. AI and deep learning enhance Moringa breeding, allowing for faster, cost-effective development of improved varieties. MO’s diverse applications establish it as a key element for sustainable development in arid regions.

18 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YVYebran Villegas-Vázquez
Yebran Villegas-Vázquez
JPJuan Ramón Padilla-Mendoza
Juan Ramón Padilla-Mendoza
MCMayra Susana Carrillo-Pérez
Mayra Susana Carrillo-Pérez
RGRocío Gómez-Cansino
Rocío Gómez-Cansino
LALiliana Altamirano-Garcia
Liliana Altamirano-Garcia
LQLaura Itzel Quintas-Granados
Laura Itzel Quintas-Granados
Moringa oleifera (MO), a nutritionally and pharmacologically potent species, is emerging as a sustainable candidate for applications across bioenergy, agriculture, textiles, pharmaceuticals, and biomedicine. This review explores recent advances in MO-based biotechnologies, highlighting novel extraction methods, green nanotechnology, and clinical trial findings. Although MO’s resilience offers promise for climate-smart agriculture and public health, challenges remain in standardizing cultivation and verifying therapeutic claims. This work underscores MO's translational potential and the need for integrative, interdisciplinary research. MO is used in advanced materials like electrospun fibers and biopolymers, showing filtration, antibacterial, anti-inflammatory, and antioxidant properties—important for the biomedical industry and environmental remediation. In textiles, it serves as an eco-friendly alternative for wastewater treatment and yarn sizing. Biotechnological advancements, such as genome sequencing and in vitro culture, enhance traits and metabolite production. MO supports green biotechnology through sustainable agriculture, nanomaterials, and biocomposites. MO shows potential for disease management, immune support, metabolic health, and dental care, but requires further clinical trials for validation. Its resilience is suitable for land restoration and food security in arid areas. AI and deep learning enhance Moringa breeding, allowing faster, cost-effective development of improved varieties. MO’s diverse applications establish it as a key element for sustainable development in arid regions.